Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Select a campus/region

Ultra-Short Echo Time (UTE) and Whole-Body MRI for visualization of Gynecological Cancer Metastases

  • Status
    Accepting Candidates
  • Age
    18 Years - 80 Years
  • Sexes
  • Healthy Volunteers


Gynecological malignancies are a significant cause of mortality among females. However, the survival rate is higher if diagnosed at an early stage. We hypothesize that magnetic resonance imaging (MRI) can feasibly and accurately stage advanced cases of gynecological cancer. We propose a novel contrast–enhanced MRI protocol which consists of T1-weighted (T1W), T2-weighted (T2W), and Diffusion Weighted Imaging (DWI) MR imaging sequences, with the Ultrashort Echo Time (UTE) sequence for the chest. UTE is an advanced MRI technique, which has shown promise in lung tissue imaging, one of the main metastatic sites for gynecological malignancies. We plan to image 5 prospective patients with biopsy-proven metastatic disease of the chest. We will investigate the feasibility of the proposed abbreviated whole-body MRI protocol for staging of gynecological malignancies as an alternative to standard-of-care fluorodeoxyglucose (FDG)-positron emission tomography (PET). The successful completion of this research will positively impact clinical protocols in cancer staging and avoid patients from unnecessary radiation utilized by PET imaging.


Protocol number IRB202200509


Inclusion Criteria

FDG-PET and biopsy-proven gynecological cancer with chest metastases Age greater than 18 and less than 81 years Female (non-pregnant, non-lactating) Able to give informed consent in any language (via the use of translation services) Able to receive contrast agent. No medically documented renal issues (to be verified during MR safety screening questionnaire) and eGFR test before the scan if it has not been done recently based on medical chart of the patient

Exclusion Criteria (General)

Pregnant and lactating females Contraindication to MRI such as pacemaker, defibrillator implants, etc. Contraindication to MR contrast agents such as renal insufficiency Claustrophobia

Subjects of all racial/ethnic groups will be recruited.  Lactating and pregnant women will be excluded, as the effects of MRI on fertility or a fetus is not known.  

Lead researchers

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step


    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.